Anti-Vegf Therapy for Ocular Diseases: Present and Future

Author(s): Claudio Campa, Maurizio Battaglia Parodi

Journal Name: Current Drug Targets

Volume 21 , Issue 12 , 2020


Become EABM
Become Reviewer
Call for Editor

[1]
Miller JW, Adamis AP, Shima DT, D’Amore PA, Moulton RS, O’Reilly MS, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-84.
[2]
Kim LA, D'Amore PA. A brief history of anti-VEGF for the treatment of ocular angiogenesis. Am J Pathol 2012; 181: 376-9.
[3]
Parodi MB, Iacono P, Da Pozzo S. Anti-VEGF and Retinal Dystrophies. Curr Drug Targets 2020. Online ahead of print
[http://dx.doi.org/10.2174/1389450121666200428103334]
[4]
Vilela MA. Use Of Anti-Vegf Drugs In Retinal Vein Occlusions Curr Drug Targets 2020. Online ahead of print
[http://dx.doi.org/10.2174/1389450121666200428101343]
[5]
Giannaccare G, Pellegrini M, Bovone C, et al. Anti-VEGF Treatment in Corneal Diseases Curr Drug Targets 2020. Online ahead of print
[http://dx.doi.org/10.2174/1389450121666200319111710]
[6]
Sorrentino FS, Jurman G, De Nadai K, Campa C, Furlanello C, Parmeggiani F. Application of Artificial Intelligence in Targeting Retinal Diseases. Curr Drug Targets 2020. Online ahead of print
[http://dx.doi.org/10.2174/1389450121666200708120646]
[7]
Claudio Campa. New Anti-Vegf Drugs In Ophthalmology. Curr Drug Targets 2020. Online ahead of print
[http://dx.doi.org/10.2174/1389450121666200428101738]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 21
ISSUE: 12
Year: 2020
Page: [1158 - 1158]
Pages: 1
DOI: 10.2174/138945012112200727153907

Article Metrics

PDF: 52
HTML: 4